CALIFORNIA THORACIC SOCIETY
ANNUAL CARMEL CONFERENCE

New Developments in the Management of Asthma and COPD

CONFERENCE PROGRAM
January 25-26, 2013 - Carmel Mission Inn, Carmel, CA

Jointly sponsored by the American Thoracic Society and the California Thoracic Society
2013 Officers

George E. Chaux, MD, President
Cedars-Sinai Medical Center, Los Angeles

Heidi R. Flori, MD, President-Elect
Children's Hospital & Research Center, Oakland

Karl Van Gundy, MD, FCCP, Past President
UCSF Department of Medicine, Fresno

Angela C. Wang, MD, Secretary-Treasurer
Scripps Clinic, La Jolla

Shannon Jamieson, Executive Director

Directors and Committee Chairs

James K. Brown, MD, Chair, Health Care Policy
VA Medical Center, San Francisco

Arthur D. Dawson, MD, Co-Chair, Proficiency Testing
Scripps Clinic, La Jolla

Heidi R. Flori, MD, Chair, Pediatric / Co-Editor, CTS Newsletter
Children's Hospital & Research Center, Oakland

Mark Goldstein, RCP, RPT
Sutter VNA Timberlake, Folsom

Angela P. Halpin, RN, MN, CNS, Chair, Pulmonary Nursing & Respiratory Care
UCLA Medical Center, Los Angeles

Russell C. Klein, MD, Chair, Education
Huntington Beach Internal Medicine Group, Corona del Mar

Jeffrey L. Kupperman, MD, Chair, Membership
Santa Barbara Pulmonary Consultants, Santa Barbara

Michael Peterson, MD, CCR Representative
UCSF Department of Medicine, Fresno

Jeffrey S. Sager, MD, Chair, Clinical Practice
Santa Barbara Pulmonary Consultants, Santa Barbara

William W. Stringer, MD, Co-Chair, Proficiency Testing
Harbor UCLA Medical Center, Torrance
# California Thoracic Society
## 2013 Carmel Conference

### SCHEDULE

#### Friday, January 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session or Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM</td>
<td>Conference Registration / Exhibits</td>
<td>Rio</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Exhibit Hall Opens</td>
<td>Tolosa</td>
</tr>
<tr>
<td>1:00 - 5:30 PM</td>
<td><strong>CTS COPD Sessions</strong></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td><strong>Welcome &gt; Pre-test</strong> - Michael Schivo, MD</td>
<td>Carmelo</td>
</tr>
<tr>
<td>1:10 PM</td>
<td><strong>Patient with Severe Emphysema Admitted for a COPD Exacerbation</strong> - Ni-Cheng Liang, MD, UCSD Pulmonary Fellow</td>
<td>Carmelo</td>
</tr>
<tr>
<td>1:25 PM</td>
<td><strong>Prevention of COPD Exacerbations</strong> - Richard Casaburi, PhD, MD, LA BioMed at Harbor-UCLA Medical Center</td>
<td>Carmelo</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>Management of COPD - Stephen Rennard, MD, University of Nebraska</td>
<td>Carmelo</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Virtual Thoracic Tumor Board - Pierre Theodore, MD, UCSF</td>
<td>Carmelo</td>
</tr>
<tr>
<td>2:55 PM</td>
<td><strong>BREAK</strong></td>
<td>Tolosa</td>
</tr>
<tr>
<td>3:15 PM</td>
<td><strong>Reducing Readmissions for COPD Exacerbations</strong> - Christine M. Garvey, FNP, MPA, MSN, FAACVPR, Seton Medical Center, UCSF</td>
<td>Carmelo</td>
</tr>
<tr>
<td>3:55 PM</td>
<td><strong>Pulmonary Rehabilitation in COPD</strong> - Andrew Ries, MD, UCSD</td>
<td>Carmelo</td>
</tr>
<tr>
<td>4:35 PM</td>
<td><strong>Palliative Care for End-Stage Lung Disease</strong> - Matthew Gonzales, MD, UCSF</td>
<td>Carmelo</td>
</tr>
<tr>
<td>5:15 PM</td>
<td><strong>Panel Discussion/Closing Comments &gt; Post-test</strong></td>
<td>Carmelo</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Welcome Reception &amp; Exhibits</td>
<td>Tolosa/Outdoor Patio</td>
</tr>
<tr>
<td>7:00 PM</td>
<td><strong>CTS/Western Respiratory Club dinner</strong> - Speaker: Faith T. Fitzgerald, MD, MACP, UC Davis - &quot;Ceremonies of Death&quot;</td>
<td>Il Fornaio Restaurant</td>
</tr>
</tbody>
</table>

#### Saturday, January 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session or Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td><strong>Tri-Society Pulmonary Sessions</strong></td>
<td>Sunset Center</td>
</tr>
<tr>
<td>9:00 AM</td>
<td><strong>California Cystic Fibrosis Consortium Meeting</strong></td>
<td>Carmelo</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Conference Registration / Exhibits</td>
<td>Rio &amp; Tolosa</td>
</tr>
<tr>
<td>1:00 - 5:30 PM</td>
<td><strong>CTS Asthma Sessions</strong></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td><strong>Introduction &gt; Pre-test</strong> - Amir Zeki, MD</td>
<td>Carmelo</td>
</tr>
<tr>
<td>1:15 PM</td>
<td><strong>A Middle Aged Woman with Severe Asthma Admitted for Respiratory Failure</strong> - Michael Peters, MD, UCSF</td>
<td>Carmelo</td>
</tr>
<tr>
<td>1:30 PM</td>
<td><strong>Managing Patients with Severe Asthma</strong> - Stephen C. Lazarus, MD, UCSF</td>
<td>Carmelo</td>
</tr>
<tr>
<td>2:25 PM</td>
<td><strong>Severe Asthma and COPD: ICU Management Guidelines and Controversies</strong> - Nicholas J. Kenyon, MD, UC Davis</td>
<td>Carmelo</td>
</tr>
<tr>
<td>3:15 PM</td>
<td><strong>BREAK</strong></td>
<td>Tolosa</td>
</tr>
<tr>
<td>3:45 PM</td>
<td><strong>An Inner City Child of Latin American Ethnicity with Severe Asthma</strong> - Mustafa Bseikri, MD, Children’s Hospital Oakland</td>
<td>Carmelo</td>
</tr>
<tr>
<td>4:00 PM</td>
<td><strong>Managing Asthma in Children: Role of Patient-Initiated Action Plans and Monitoring</strong> - Fernando Martinez, MD, University of Arizona</td>
<td>Carmelo</td>
</tr>
<tr>
<td>4:50 PM</td>
<td><strong>Improving Asthma Control in Patients of Hispanic and African American Ethnicity</strong> - Grace E. Hardie, PhD, RN, UCSF, SF State</td>
<td>Carmelo</td>
</tr>
<tr>
<td>5:30 PM</td>
<td><strong>Panel Discussion/Closing Comments &gt; Post-test</strong></td>
<td>Carmelo</td>
</tr>
</tbody>
</table>

#### Sunday, January 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session or Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td><strong>CTS Golf Tournament</strong></td>
<td>Poppy Hills Golf Course</td>
</tr>
</tbody>
</table>
Carmel Mission Inn
3665 Rio Road, Carmel, CA

A = Carmelo Room
B = Tolosa Room
C = Dolores Room
D = Rio Room

Nestled amongst the spectacular floral gardens and rolling green hills of Carmel Valley, the Carmel Mission Inn is surrounded by over 160 boutique shops/restaurants and located at the gateway to the Monterey Wine Country just 1 mile from the pristine central California coastline.
# Faculty List

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mustafa Bseikri, MD (Fellow)</td>
<td>Children’s Hospital Oakland</td>
<td>Oakland, CA</td>
</tr>
<tr>
<td>Richard Casaburi, PhD, MD</td>
<td>LA BioMed at Harbor – UCLA Medical Center</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>Chris Garvey, FNP, MPA, MSN, FAACVPR</td>
<td>Seton Medical Center, UCSF</td>
<td>Daly City, CA</td>
</tr>
<tr>
<td>Matthew Gonzales, MD</td>
<td>UCSF</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Grace E. Hardie, PhD, RN</td>
<td>UCSF, San Francisco State</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Nicholas J. Kenyon, MD</td>
<td>UC Davis</td>
<td>Davis, CA</td>
</tr>
<tr>
<td>Stephen C. Lazarus, MD</td>
<td>UCSF</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Ni-Cheng Liang, MD (Fellow)</td>
<td>UCSD Pulmonary Fellow</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Fernando Martinez, MD</td>
<td>University of Arizona</td>
<td>Tucson, AZ</td>
</tr>
<tr>
<td>Michael Peters, MD (Fellow)</td>
<td>UCSF</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Stephen Rennard, MD</td>
<td>University of Nebraska</td>
<td>Lincoln, NE</td>
</tr>
<tr>
<td>Andrew Ries, MD</td>
<td>UCSD</td>
<td>San Diego, CA</td>
</tr>
</tbody>
</table>

# Conference Planning Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Schivo, MD, Co-Chair</td>
<td>UC Davis Medical Center</td>
<td>Davis, CA</td>
</tr>
<tr>
<td>Angela C. Wang, MD, Education Chair</td>
<td>Scripps Clinic</td>
<td>La Jolla, CA</td>
</tr>
<tr>
<td>Amir Zeki, MD, MAS, Co-Chair</td>
<td>UC Davis Medical Center</td>
<td>Davis, CA</td>
</tr>
<tr>
<td>Angela Halpin, RN, MN, CNS</td>
<td>UCLA</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>Russell C. Klein, MD, Co-Chair</td>
<td>Huntington Beach Internal Medicine Group</td>
<td>Corona del Mar, CA</td>
</tr>
<tr>
<td>Christine M. Garvey, FNP, MPA, MSN, FAACVPR</td>
<td>Seton Medical Center, UCSF</td>
<td>Daly City, CA</td>
</tr>
</tbody>
</table>
COPD Sessions - Friday, January 25

Ni-Cheng Liang, MD
UCSD Pulmonary Fellow
**Patient with Severe Emphysema Admitted for a COPD Exacerbation**

Richard Casaburi, PhD, MD
LA BioMed at Harbor-UCLA Medical Center
**Prevention of COPD Exacerbations**

Stephen Rennard, MD
University of Nebraska
**Management of COPD**

Pierre Theodore, MD
UCSF
**Virtual Thoracic Tumor Board**

Christine M. Garvey, FNP, MPA, MSN, FAACVPR
Seton Medical Center, UCSF
**Reducing Readmissions for COPD Exacerbations**

Andrew Ries, MD
UCSD
**Pulmonary Rehabilitation in COPD**

Matthew Gonzales, MD
UCSF
**Palliative Care for End-Stage Lung Disease**
Asthma Sessions- Saturday, January 26

Michael Peters, MD
UCSF
A Middle Aged Woman with Severe Asthma Admitted for Respiratory Failure

Stephen C. Lazarus, MD
UCSF
Managing Patients with Severe Asthma

Nicholas J. Kenyon, MD
UC Davis
Severe Asthma and COPD: ICU Management Guidelines and Controversies

Mustafa Bseikri, MD
Children’s Hospital Oakland
An Inner City Child of Latin American Ethnicity with Severe Asthma

Fernando Martinez, MD
University of Arizona
Managing Asthma in Children: Role of Patient-Initiated Action Plans and Monitoring

Grace E. Hardie, PhD, RN
UCSF, SF State
Improving Asthma Control in Patients of Hispanic and African American Ethnicity
**Aerocrine**  
**Products/Services Offered:** NIOX Flex and NIOX MINO  
**Company Profile:** Aerocrine is a medical technology company focused on improving the management and care of patients with inflammatory airway diseases, such as asthma. As the pioneer and leader in FeNO technology, Aerocrine markets NIOX MINO® to monitor and manage airway inflammation. NIOX MINO® enables fast and reliable detection of airway inflammation to help identify, treat, and manage patients who might benefit from anti-inflammatory medicine. For more information, visit www.aerocrine.com.  
**Contact(s):** John Borrelli (john.borrelli@aerocrine.com); Shari Judy (shari.judy@aerocrine.com)

**AstraZeneca**  
**Products/Services:** Symbicort  
**Company Profile:** AstraZeneca is a global, innovation-driven, integrated biopharmaceutical business. We focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.  
**Contact(s):** Scott Elder (scott.elder@astrazeneca.com); Anhchi Busboom

**Baxter Healthcare**  
**Products/Services:** Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.  
**Contact(s):** Dax Ortiz (dax_ortiz@baxter.com); Rob Rehfeld (rob_rehfeld@baxter.com)

**Boehringer Ingelheim Pharmaceuticals, Inc.**  
**Products/Services:** SPIRIVA®, Combivent® Respimat®  
**Company Profile:** The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.  
**Contact(s):** Jeffrey Wong (jeffrey.wong@boehringer-ingelheim.com)

**Boston Scientific**  
**Products/Services:** Alair Bronchial Thermoplasty System, that is used in a safe outpatient procedure that provides a long-term reduction in asthma attacks for people with severe asthma  
**Company Profile:** Boston Scientific has developed a bronchoscopic procedure for the treatment of severe asthma in adults not well controlled on ICS and LABA alone. The Alair® Bronchial Thermoplasty System reduces the amount of excessive airway smooth muscle, decreasing the ability of the airway walls to contract and narrow during an asthma attack, providing long-lasting and improved asthma control for adult asthma patients. For more information, please visit www.BTforAsthma.com  
**Contact(s):** Lisa Ivey (lisa.ivey@bsci.com)

**California Smokers' Helpline - UCSD, Moores Cancer Center**  
**Products/Services:** Telephone counseling for smoking cessation  
**Company Profile:** The California Smokers Helpline - UCSD provides free telephone counseling for people who want to quit smoking or chewing tobacco in California. The Helpline also offers free materials.  
**Contact(s):** Samia Hamnache (shamnache@ucsd.edu)
CareFusion

Company Profile: At CareFusion, we are united in our vision to improve the safety and lower the cost of healthcare for generations to come. Our 14,000 worldwide employees are passionate about healthcare and helping those that deliver it - from the hospital pharmacy to the nursing floor, the operating room to the patient bedside. Our clinically proven product families include Pyxis® for medication and supply dispensing, Alaris® for infusion, AVEA® ventilators, Jaeger® for respiratory diagnostic instruments, AVAm®x and PluerX® for interventional procedures, V. Mueller® and Snowden-Pencer® surgical instruments, and Chloraprep® skin antiseptic.

Contact(s): Kevin Cole (kevin.cole@carefusion.com)

CSL Behring

Products/Services: Zemaira is approved by the FDA for chronic augmentation and maintenance therapy in adults with Alpha-1 and emphysema.

Company Profile: CSL Behring is with you every step of the way, offering Alpha-1 patients the support of the CareZ community, a comprehensive suite of services that helps make access to treatment easier. CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies to treat rare, often life-threatening conditions. Our customers rely on our therapies to help them live better and, in many cases, longer lives. CSL Behring’s commitment to changing the lives of people with serious and rare conditions shows in everything we do. Whether manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, our first and foremost focus is always on fulfilling our customers' needs.

Contact(s): Timothy Collard (tim.collard@cslbehring.com)

Cystic Fibrosis Services

Company Profile: CF Services is affiliated with Walgreens and the Cystic Fibrosis Foundation and was established in 1988 as a specialty pharmacy specializing in CF medications, patient advocacy and reimbursement support. CF Services is a full-service pharmacy, managed by the highly regarded Walgreens Company founded in 1901, is your one-stop shop for all your prescription medication needs. Since its inception in 1988, CF Services is unequaled in providing outstanding pharmacy services for individuals with CF.

Contact(s): Cesar Castellon (ccastellon@cfserv.com)

Forest Pharmaceuticals

Company Profile: Forest has well-established franchises in the therapeutic areas of the central nervous and cardiovascular systems, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include Tudorza®Pressair® (aclidinium bromide), Bystolic® (nebivolol), Daliresp® (roflumilast), Lexapro® (escitalopram oxalate), Namenda® (memantine HCl), Savella®(milnacipran HCl), Tefflar® (ceftaroline fosamil) for injection, Linzess® (linaclotide), and Viibryd® (vilazodone HCl).

Contact(s): Eddie Dean (Eddie.Dean@frx.com); Sue Herdt (sue.herdt@frx.com)
Amy Solanas (Amy.Solanas@frx.com)

Genentech

Company Profile: Considered the founder of the industry, Genentech has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Contact(s): Marisa Rapport (fusco@gene.com)
Genzyme Therapeutics
Company Profile: Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Contact(s): Ginger Gradeff (ginger.gradeff@genzyme.com)
Valerie Silva (Valerie.Silva@genzyme.com)
Lauren Nelson (lauren.nelson@genzyme.com)

Gilead Sciences, Inc.
Company Profile: Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation.
Contact(s): Tim Cochrane (tim.cochrane@gilead.com)

Hill-Rom
Products/Services: The Vest® and MetaNeb®
Company Profile: Hill-Rom is a leading worldwide manufacturer and provider of medical technologies and services for the health care industry. We are a company that draws on a heritage of more than 80 years of innovation and excellence to provide solutions that enhance outcomes for our patients and their caregivers. Hill-Rom's The Vest® Airway Clearance System has been prescribed for over 123,000 patients, with a variety of conditions, to aid in the mobilization of retained secretions. Our newest product addition, The MetaNeb® System, is indicated for lung expansion therapy, the mobilization of secretions, and the treatment and prevention of pulmonary atelectasis.
Contact(s): Kari Larsen (kari.larsen@hill-rom.com); Mark Wolski (mark.wolski@hill-rom.com)

ModernHealthcare, Inc.
Company Profile: ModernHEALTH provides a fully integrated suite of pharmacy services, giving our customers the convenience of a single source provider and the flexibility of selecting the medications and services that meet their individual needs. Since 1975, we have remained an independently owned and operated corporation. Improving the pharmacy care of patients is at the heart of service development at ModernHEALTH.
Contact(s): Sherri Cherman (scherman@modernhealthinc.com)

Novartis Pharmaceuticals Corporation
Company Profile: Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health. We are committed to serving as a responsible corporate citizen. Our commitment to stockholders, employees, customers, suppliers and the communities in which we live and work, is an integral part of how we operate and a key to our success.
Contact(s): David Lee; Carlyl Sole
Novartis Pharmaceuticals Corporation
Products/Services: Arcapta Neohaler
Contact(s): Robin Fena (robin.fena@novartis.com)

Products/Services: XOLAIR®
Contact(s): Polly Murphy (pollymurphy@novartis.com)
Michelle Hurley (michele.hurley@novartis.com)

RespirTech
Company Profile: The InCourage Airway Clearance System (High Frequency Chest Compression) is widely prescribed for patients with numerous pulmonary and non-pulmonary conditions that may compromise ability to clear pulmonary secretions. The InCourage system offers state of the art airway clearance therapy incorporating the most recent advances in high-frequency chest compression.
Contact(s): Kim Wilcox (kwilcox@respirtech.com); Kellye Tarelka (ktarelka@respirtech.com)

Smiths Medical - Northern California, Nevada
Products/Services: Respiratory Products - Lung Expansion and Bronchial Hygiene
Company Profile: Smiths Medical is a leading global provider of medical devices for the hospital, emergency, home and specialist environments. Our products are used during critical and intensive care, surgery, and post-operative care during recovery, and in a series of high-end home infusion therapies. The parent company is Smiths Group based in the United Kingdom.
Contact(s): Wayne Richart (wayne.richart@smiths-medical.com)
Yvonne Lewis (Yvonne.lewis@smiths-medical.com)

Teva Pharmaceutical Industries
Products/Services: QVAR; ProAir HFA; QNASL. Respiratory Products- Asthma COPD, EIB, Allergic Rhinitis.
Company Profile: Teva is a global leader in generic pharmaceuticals and has one of the broadest product portfolios in the industry. Teva's long tradition of dedication to excellence is demonstrated in the development, production and marketing of a unique and wide range of generic and branded pharmaceuticals, as well as Active Pharmaceutical Ingredients (API).
Contact(s): Jeff Rahilly (jeff.rahilly@tevapharm.com); Mark Hill (mark.hill@tevapharm.com)

US Army Health Care
Products/Services: Medical recruitment within the U.S. Armed Forces Military Health Systems.
Company Profile: U.S. Army healthcare recruitment.
Contact(s): Albert Matel (albert.matel@usarec.army.mil)
Rebecca Carcabuso (Rebecca.Carcabuso@usarec.army.mil)

Vertex Pharmaceuticals, Inc.
Company Profile: Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. In addition to our approved medicines, we are developing new combinations of medicines that could further advance treatment of hepatitis C and cystic fibrosis and is interested in supporting CF and CF centers.
Contact(s): Kristin Bleyl (kristin_bleyl@vrtx.com); Michelle Faust (michelle_faust@vrtx.com)